Table 5 Association between CD8+ T cell subsets at baseline and clinical outcome after ICI
Biomarker | NSCLC stage (n) | Treatment | Direction at baseline | Association with clinical outcome | Ref | |||
|---|---|---|---|---|---|---|---|---|
Response | PFS | OS | ||||||
CD8 | % Ki67+CD8+ T cells | Advanced NSCLC (n = 40); HNSCC (n = 41) | αPD-1 | ↑ | ↑ (p = 0.085) | ↑ (p = 0.048) | [28] | |
% CD8+CD45RA−CD62L− | Advanced NSCLC (n = 40); HNSCC (n = 41) | αPD-1 | ↑ | ↑ (p = 0.019) | ns | |||
CD8+ memory stem cells counts | III-IV (n = 92) | αPD-L1, αPD-L1/chemo | ↑ | ↑ (p = 0.006) | [70] | |||
CD8+CXCR4+ | Advanced (n = 36) | αPD-1 | ↑ | ns | ↓ (p = 0.0256) | [72] | ||
% CD8+CD28−CD57+KLRG1+ (SIP) | III-IV (n = 83) | αPD-1, αPD-L1 | ↑ | ↓ (p = 0.002) | ↓ (p < 0.0001) | ↓ (p = 0.007) | [73] | |
ratio of CD8+PD-1+ to CD4+PD-1+ (PERLS) | III-IV (n = 111) | αPD-1, αPD-L1 | ↑ | ↑ (p = 0.0017) | ↑ (p = 0.0039) | ↑ (p = 0.0239) | [74] | |
SIP and PERLS | III-IV (n = 111) | αPD-1, αPD-L1 | ↓SIP, ↑PERLS | ↑ (p < 0.0001) | ↑ (p = 0.001) | |||
CD8+PD-1+, NK cells, sPD-L1 (IeffS) | IIIB-IV (n = 109) | αPD-1, αPD-L1 | no risk | ↑ (p = 0.002) | ↑ (p < 0.001) | ↑ (p < 0.001) | [75] | |